Infosys Launches SAP-based Personalized Medicine Solution for Pharmaceutical Companies

Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced the launch of an all-new, Personalized Medicine solution for the pharmaceutical industry. The solution leverages SAP S/4HANA®, the SAP C/4HANA® suite, the SAP® Analytics Cloud solution, and SCI® platform to derive intelligent insights, enabling pharmaceutical companies to address critical business and regulatory requirements while delivering personalized experiences to patients.

The Infosys Personalized Medicine Solution enables pharma companies to digitally transform their processes and drive stronger business outcomes. The modular solution uses advanced analytics to manage individual patient treatment lifecycle from enrollment and scheduling to post medical treatments and can notably reduce patient treatment lifecycle. It uses IoT and blockchain to manage critical cold chains and outcome-based invoicing. The solution incorporates seamlessly into an existing business process with minimal disruptions, reducing implementation time, thus enabling quicker product launches for pharma companies.

Subhro Mallik, SVP & Global Head of Life Sciences, Infosys said, “With rapid growth in digital technologies and advances in biology, the personalized medicine market is projected to grow significantly, and we see a huge opportunity in this space.  Digital technologies can help pharma companies accelerate their time to market and provide better patient experiences. Our Personalized Medicine Solution, leveraging SAP S/4HANA, will help ensure that traditional pharma companies are able to digitally transform themselves with minimum disruption.”

Saurabh Gupta, Chief Research Officer, HfS, said, "Consumer-centricity has emerged as the #1 strategic objective across the healthcare and life sciences industry. I am most excited about the personalized comprehensive visibility and transparency that this solution from Infosys and SAP offers to the patient by bringing together the complex network of entities (payer, provider, and pharma) that they have to deal with."

Joe Miles, SVP and Head of HCLS Business Unit at SAP, said, “Global pharmaceutical companies are using SAP S/4HANA to drive new therapeutic models such as Personalized Medicine. To make this possible, life sciences leaders are disrupting their business models and supply chains to successfully deliver these life-saving and individualized therapies. Organizations must evolve from a traditional “make to stock” model to a highly personalized “make to order” model. This requires aggregating and analyzing massive amounts of genomic, therapeutic and patient data, in real time, to execute an end-to-end process, at scale. SAP S/4HANA provides a digital core to help enable the intelligent life sciences enterprise and deliver these remarkable drugs and devices. The partnership of SAP S/4HANA with Infosys’ Personalized Medicine Solution will allow organizations to leverage their SAP S/4HANA digital core investments, combined with Infosys’ thought-leading expertise, to enable our customers’ growth and scale in this new market.”

For more information, please visit: https://www.infosys.com/industries/life-sciences/features-opinions/personalizing-medicine-intelligent.html

About Infosys

Infosys is a global leader in next-generation digital services and consulting. We enable clients in 46 countries to navigate their digital transformation. With nearly four decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.

Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, financial expectations and plans for navigating the COVID-19 impact on our employees, clients and stakeholders are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of government and other measures seeking to contain its spread, risks related to an economic downturn or recession in India, the United States and other countries around the world, changes in political, business, and economic conditions, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigation. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2019. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

Media contacts:

For further information, please contact: PR_Global@infosys.com